https://www.selleckchem.com/pr....oducts/pd-1-pd-l1-in
Rheumatoid arthritis (RA) clinical guidelines do not provide strong recommendations for the choice of disease-modifying anti-rheumatic drugs (DMARD) in patients with an inadequate response to methotrexate (MTX), and only limited evidence is available on factors influencing rheumatologist treatment decisions. We aimed to describe therapeutic preferences after the failure of a first-line strategy of MTX in simulated cases of patients with RA. Fictional but realistic case-vignettes (n = 64) of patients with RA and an inadequ
Gefällt mir
nicht gefallen
Kommentar
Teilen
